Our minor, novel & synthetic cannabinoid series concludes with Part V looking at different approaches to regulating consumer products containing cannabinoids across the US and provide perspectives from cannabinoid product manufacturers on the impact these varying regulations have on their business.

Regulating the cannabinoids is difficult enough, but throw in the challenges associated with cannabinoids derived from marijuana or hemp and the challenges can get even more complicated. Not to mention the debate between intoxicating and non-intoxicating cannabinoids and how to address the risks to public health and safety from these different types of cannabinoids. Then you have the proverbial “cherry on top” with how to address cannabinoids, both naturally occurring and novel, being produced by genetically modified organisms and scientists in the lab. There has got to be a logical way to solve this problem.

One potential solution is shifting the conversation away from cannabis vs. hemp and toward the constituents of concern, the cannabinoids. By regulating the cannabinoids, we can focus the debate on what matters, how to regulate cannabinoid ingredients in a way that is proportional to the level of risk to public health and safety. This ensures we have both a functional and vibrant cannabinoid products market and the means to protect consumers.

Panelists will conclude by discussing what harmonized regulations for consumer products containing cannabinoids might look like in the future.

Learning Objectives:

• Learn about the similarities and differences between marijuana and hemp regulations for consumer products containing cannabinoids
• Find out what a consumer product containing cannabinoids is and how this concept can be used to promote more common sense regulations
• Listen to new perspectives on the challenges facing the cannabinoid-containing consumer products space and how to more efficiently regulate this marketplace

Panelists

Chris Hope (Moderator)
Founder and Consultant
Sequoia Management Group

James Granger
Chief Political Officer
Cliintel Capital Group

Darwin Millard
Chief Scientific OfficerCanada
Final Bell

Keith Butler
CEO
OP Innovates / Naturia+

Cassin Coleman
Founder
Cassin Consulting

Gillian Schauer
Executive Director
Cannabis Regulators Association